News

The World Health Organisation1 estimates that over 1.5 million people die from tuberculosis (TB) worldwide, making it the second leading infectious disease killer after COVID-19. Caused by the bacterium Mycobacterium tuberculosis, TB is an infectious disease that has plagued humankind for more than 70,000 years2, with an estimated 10 million new cases of TB annually. […]

EDDC’s Biomarker team analysing samples from ETC-159 trialA made-in-Singapore cancer drug, ETC-159, has advanced into the dose expansion portion of its Phase 1B clinical trial. The Phase 1B dose expansion study tests the preliminary efficacy and safety of ETC-159 in a subset of genetically defined patients with microsatellite stable (MSS)1 cancers. MSS tumours have few

The following text is adapted from this press release. EDDC staff planning the automation of an antibody engineering process. Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for specific targeting of tumor cells without binding to healthy cells

In 2018, local biotech start-up AUM Biosciences (AUM) was looking to kick-off an “Asia to Global” vision through a focus on developing therapeutics for Asia-Pacific cancers, which could also be delivered to Western markets. That year, the oncology research company licensed ETC-206, now known as AUM001, a MNK inhibitor that was developed by a legacy

Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19 Everest will have sub-licensing rights and full technology transfer Licensing of 3CL protease inhibitor oral treatment is expected to complement Everest’s COVID-19 vaccine program Clinical trials evaluating lead asset EDDC-2214 expected to start later this year Shanghai, China — January

This is an excerpt of an article in Duke-NUS Medicus 2021 issue 4. The (Wnt)ing way: Fighting cancer with ETC-159Wnts, which instruct cells on what they should become, are only found in multicellular animals, but not in single cell organisms such as yeast or amoebas, which don’t have as much need for proteins that communicate

While COVID-19, a disease caused by a virus, has captured the world’s attention over the past year, bacterial infections continue unabated. Furthermore, the emergence of more and more “superbugs” that are resistant to current treatment only serves to compound the issue, often leading to deadly outcomes. The Mycobacterium tuberculosis (Mtb) bacteria that causes tuberculosis (TB)

These compounds target the SARS-CoV-2 main protease and are active against other coronaviruses Lead series of proprietary 3CLpro inhibitors is available for out-licensing or co-development to expedite development and make an oral drug available to patients. As Singapore transitions “from pandemic to endemic”, its scientists are still working hard to find solutions to tackle COVID-19.

The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted at the Agency for Science, Technology and Research (A*STAR), and Hummingbird Bioscience, a clinical-stage biotech company, have entered a three-year partnership to develop novel antibodies for cancer immunotherapy. Immunotherapy can harness and enhance our body’s own immune defenses to fight

On 5 February 2021, Experimental Drug Development Centre (EDDC) hosted a visit by Second Minister for Trade and Industry, Dr Tan See Leng. This visit was part of Dr Tan’s monthly engagement visit with A*STAR research organisations to better understand the R&D scene in Singapore and to stay apprised of significant developments in A*STAR. Dr